ScholarIQanswers from OpenAlex
ActionAid
InstitutionResearch output, impact & collaborations
ActionAid is a institution indexed in ScholarIQ from OpenAlex.
What is known about ActionAid?
ScholarIQrecord summary
ActionAid is a research organisation in Washington D.C., US. OpenAlex records 1,815 works and 64,972 citations for it. 712 researchers list it as their most recent affiliation.
How many works does ActionAid have?
ScholarIQindexed works
ActionAid has 1,815 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does ActionAid have?
ScholarIQcitation count
ActionAid has 64,972 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at ActionAid?
ScholarIQresearcher count
ActionAid has 712 researchers in the ScholarIQ index.
What is the average h-index at ActionAid?
ScholarIQavg h-index
ActionAid has an average h-index of 28 in OpenAlex.
What is the ROR of ActionAid?
ScholarIQror
The ROR for ActionAid is on the source record.
What is the OpenAlex record for ActionAid?
ScholarIQopenalex
The OpenAlex for ActionAid is on the source record.
What is the Wikidata of ActionAid?
ScholarIQwikidata
The Wikidata for ActionAid is on the source record.
Who are the most-cited researchers behind ActionAid?
ScholarIQtop researchers by citations
What are the most-cited papers on ActionAid?
ScholarIQmost cited works
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Jared J. Grantham, Eiji Higashihara, Ronald D. Perrone, Holly B. Krasa, John Ouyang, Frank S. Czerwiec
Prevalence of autosomal dominant polycystic kidney disease in the European Union
Cynthia Willey, Jaime D. Blais, Anthony K Hall, Holly B. Krasa, Andrew Makin, Frank S. Czerwiec
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
Paul B. Watkins, James H. Lewis, Neil Kaplowitz, David Alpers, Jaime D. Blais, Dan M. Smotzer, Holly B. Krasa, John Ouyang, Vicente E. Torres, Frank S. Czerwiec, Christopher A. Zimmer
Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction
James E. Udelson, Cesare Orlandi, John Ouyang, Holly B. Krasa, Christopher A. Zimmer, Geir Frivold, W. Herbert Haught, Sheiba Meymandi, Cezar Macarie, Dimitar Raef, Patricia Wedge, Marvin A. Konstam, Mihai Gheorghiade
Continental Differences in Clinical Characteristics, Management, and Outcomes in Patients Hospitalized With Worsening Heart Failure
John E. Blair, Faı̈ez Zannad, Marvin A. Konstam, Thomas D. Cook, Brian Traver, John C. Burnett, Liliana Grinfeld, Holly B. Krasa, Aldo P. Maggioni, Cesare Orlandi, Karl Swedberg, James E. Udelson, Christopher Zimmer, Mihai Gheorghiade
How much of the research on ActionAid is open access?
ScholarIQopen access share
82%OPEN ACCESS